BDF
ELV icon

Balasa Dinverno & Foltz’s Elevance Health ELV Stock Holding History

Balasa Dinverno & Foltz’s Portfolio ELV Stock Details ELV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$1.69M Sell
3,711
-35
-0.9% -$16.7K 0.11% 80
2022
Q2 		$1.81M Sell
3,746
-40
-1% -$19.8K 0.11% 74
2022
Q1 		$1.86M Buy
3,786
+788
+26% +$360K 0.13% 74
2021
Q4 		$1.39M Sell
2,998
-106
-3% -$44.6K 0.09% 99
2021
Q3 		$1.16M Buy
3,104
+117
+4% +$44.5K 0.08% 109
2021
Q2 		$1.14M Sell
2,987
-11
-0.4% -$4.2K 0.08% 113
2021
Q1 		$1.08M Sell
2,998
-387
-11% -$124K 0.09% 108
2020
Q4 		$1.09M Buy
3,385
+243
+8% +$74.6K 0.09% 97
2020
Q3 		$844K Buy
3,142
+165
+6% +$44.4K 0.08% 108
2020
Q2 		$783K Sell
2,977
-141
-5% -$37.6K 0.09% 99
2020
Q1 		$708K Sell
3,118
-609
-16% -$166K 0.09% 105
2019
Q4 		$1.13M Sell
3,727
-672
-15% -$185K 0.12% 85
2019
Q3 		$1.06M Buy
4,399
+68
+2% +$18.6K 0.12% 86
2019
Q2 		$1.22M Sell
4,331
-584
-12% -$160K 0.14% 70
2019
Q1 		$1.41M Buy
4,915
+216
+5% +$62.5K 0.17% 54
2018
Q4 		$1.23M Buy
4,699
+893
+23% +$246K 0.15% 62
2018
Q3 		$1.04M Buy
3,806
+176
+5% +$45.7K 0.12% 73
2018
Q2 		$864K Buy
3,630
+97
+3% +$22.5K 0.13% 74
2018
Q1 		$776K Buy
3,533
+101
+3% +$23.7K 0.12% 76
2017
Q4 		$772K Buy
3,432
+102
+3% +$21.7K 0.11% 78
2017
Q3 		$632K Buy
3,330
+240
+8% +$45.7K 0.1% 92
2017
Q2 		$581K Buy
3,090
+253
+9% +$45.5K 0.09% 96
2017
Q1 		$469K Buy
2,837
+74
+3% +$11.8K 0.08% 109
2016
Q4 		$397K Sell
2,763
-364
-12% -$48.7K 0.07% 121
2016
Q3 		$392K Buy
3,127
+6
+0.2% +$775 0.07% 116
2016
Q2 		$410K Sell
3,121
-1,154
-27% -$158K 0.07% 108
2016
Q1 		$594K Buy
4,275
+277
+7% +$37K 0.11% 74
2015
Q4 		$557K Sell
3,998
-3,045
-43% -$419K 0.09% 81
2015
Q3 		$986K Buy
7,043
+96
+1% +$14.4K 0.17% 44
2015
Q2 		$1.14M Buy
6,947
+1,795
+35% +$287K 0.19% 35
2015
Q1 		$796K Buy
5,152
+2,209
+75% +$315K 0.11% 56
2014
Q4 		$370K Buy
+2,943
New +$364K 0.05% 122

Other funds holding ELV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Balasa Dinverno & Foltz's ELV Position: Q3 2022 in Review

Balasa Dinverno & Foltz reduced its Elevance Health (ELV) stake by 0.93% in Q3 2022, selling an estimated $16.7K and leaving 3,711 shares worth $1.69M. The position accounts for 0.11% of the portfolio, ranked #80.

Balasa Dinverno & Foltz first reported a position in ELV in Q4 2014 and has held it in 32 quarters since. The position peaked at $1.86M in Q1 2022. 1,445 funds tracked by Wall St. Rank hold ELV as of Q3 2022.

  • Balasa Dinverno & Foltz held 3,711 shares of Elevance Health worth $1.69M as of Q3 2022.
  • Balasa Dinverno & Foltz sold 35 Elevance Health shares in Q3 2022, an estimated $16.7K.
  • Elevance Health made up 0.11% of Balasa Dinverno & Foltz's portfolio in Q3 2022, its #80 holding.
  • Balasa Dinverno & Foltz first reported a position in Elevance Health in Q4 2014 and has held it in 32 quarters since.
  • Balasa Dinverno & Foltz's Elevance Health position peaked at $1.86M in Q1 2022.
  • 1,445 funds tracked by Wall St. Rank held Elevance Health as of Q3 2022.

Based on Balasa Dinverno & Foltz's 13F filing for Q3 2022, filed 25 Oct 2022.